Title |
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
|
---|---|
Published in |
Clinical Pharmacology : Advances and Applications, April 2013
|
DOI | 10.2147/cpaa.s42689 |
Pubmed ID | |
Authors |
Craig A Portell, Candice M Wenzell, Anjali S Advani |
Abstract |
Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered proteins. The bispecific T-cell-engaging antibody blinatumomab engages polyclonal T cells to CD19-expressing B cells. By binding to both CD3 and CD19, blinatumomab physically brings these T cells in close proximity to malignant B cells and potentiates T-cell-induced cytotoxic cell kill. Blinatumomab requires continuous intravenous infusion due to its short half-life, the need for continuous exposure for the drug to exert sufficient efficacy, and lessened toxicity. A phase II trial of B-cell ALL patients with persistent or relapsed minimal residual disease demonstrated an 80% rate of complete molecular remission. Cytokine-release syndrome and central nervous system events, such as seizures and encephalopathy, are reversible toxicities. Promising results in B-cell ALL with minimal residual disease have led to further evaluation of this drug in newly diagnosed and relapsed B-cell ALL. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
United States | 1 | <1% |
Germany | 1 | <1% |
Unknown | 136 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 27 | 19% |
Student > Ph. D. Student | 23 | 17% |
Student > Bachelor | 16 | 12% |
Student > Master | 15 | 11% |
Student > Doctoral Student | 9 | 6% |
Other | 19 | 14% |
Unknown | 30 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 21% |
Agricultural and Biological Sciences | 26 | 19% |
Biochemistry, Genetics and Molecular Biology | 23 | 17% |
Chemistry | 6 | 4% |
Immunology and Microbiology | 6 | 4% |
Other | 16 | 12% |
Unknown | 33 | 24% |